Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel
NASDAQ:BYSI

BeyondSpring Q3 2026 Earnings Date & Estimates

BeyondSpring logo
$0.68 +0.06 (+9.34%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$0.67 -0.01 (-1.33%)
As of 06:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from BeyondSpring in Q3 2026

BeyondSpring is expected to post earnings of -$0.54 per share on revenue of $8.77 million. BeyondSpring last reported on August 14, 2026, posting -$0.02 per share and beating the -$0.54 consensus estimate. BeyondSpring has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.54
Expected Revenue
$8.77 million

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.02 (Beat by +$0.52)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

BeyondSpring Q3 2026 Earnings FAQ

BeyondSpring (NASDAQ:BYSI) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

BeyondSpring's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect BeyondSpring to post earnings of -$0.54 per share for Q3 2026.

The consensus revenue estimate for BeyondSpring is $8.77 million for Q3 2026.

BeyondSpring Earnings Headlines

BeyondSpring Shareholders Ratify 2026 Auditor Appointment
October 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/beyondspring-shareholders-ratify-2026-auditor-appointment?utm_source=marketbeat.com&utm_medium=referral
BeyondSpring Faces Nasdaq Listing Compliance Risk
October 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/beyondspring-faces-nasdaq-listing-compliance-risk?utm_source=marketbeat.com&utm_medium=referral
What Elon Musk's Cybercab Reveal Could Mean for Investors
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.tc pixel
November 5 at 1:00 AM  |  Brownstone Research (Ad)
BeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLC
September 29, 2026  |  marketscreener.comM
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950672-beyondspring-inc-bysi-discusses-fda-fast-track-designation-and-strategic-transaction-for
BeyondSpring Gets FDA Fast Track For Plinabulin In Lung Cancer
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694750/beyondspring-gets-fda-fast-track-for-plinabulin-in-lung-cancer.aspx
See More BeyondSpring Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email.

About BeyondSpring

BeyondSpring (NASDAQ:BYSI) (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects.

Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment. BeyondSpring has also studied the candidate in combination with chemotherapy for patients with advanced or metastatic cancer, including non-small cell lung cancer.

Founded in 2010, BeyondSpring has conducted clinical development activities in the United States, China and other international markets. The company was co-founded and is led by Lan Huang, Ph.D., who has served as its chief executive officer and chairman. As a clinical-stage company, BeyondSpring’s products remain subject to regulatory review and successful clinical development.

View BeyondSpring Profile
Earnings Tools